Pharmascience Faces Six-Year Wait On Canadian Invega Sustenna
Key Canadian Patent Not Obvious And Is Patentable Subject Matter
Pharmascience has failed in a two-pronged validity challenge to a key patent shielding Janssen’s Invega Sustenna treatment for schizophrenia.
You may also be interested in...
In a dramatic twist, Gilenya ANDA sponsors are now unable to launch their generic products in the US after the US Supreme Court intervened in favor of originator Novartis, superseding the US Federal Circuit.
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.